Shilpa Medicare (SHILPAMED)₹933.85−2.08%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Shilpa Medicare reported sales of ₹464 Cr, up 45.1% from Jun 2025, and net profit of ₹101 Cr, up 114.9% year on year. For the year to Mar 2026, sales were ₹1,533 Cr and net profit ₹243 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 312 | 286 | 291 | 292 | 343 | 318 | 330 | 320 | 369 | 408 | 435 | 464 |
| Expenses | 256 | 223 | 223 | 223 | 259 | 240 | 253 | 232 | 263 | 297 | 318 | 331 |
| Operating Profit | 57.73 | 64.73 | 69.77 | 69.70 | 85.68 | 80.63 | 78.66 | 90.60 | 108 | 114 | 119 | 136 |
| OPM % | 19.0% | 23.0% | 24.0% | 24.0% | 25.0% | 25.0% | 24.0% | 28.0% | 29.0% | 28.0% | 27.0% | 29.0% |
| Other Income | 1.99 | 1.99 | 8.98 | 9.98 | 4.99 | 1.99 | −20.95 | 5.99 | 1.99 | −12.97 | 44.94 | 8.98 |
| Interest | 22.98 | 25.96 | 23.99 | 23.97 | 25.99 | 11.99 | 13.99 | 18.97 | 15.98 | 10.99 | 13.98 | 11.99 |
| Depreciation | 28.06 | 27.08 | 27.06 | 27.08 | 28.09 | 29.05 | 29.08 | 29.06 | 30.08 | 30.07 | 31.08 | 35.07 |
| Profit before tax | 9.01 | 14.01 | 27.98 | 28.99 | 37.01 | 41.97 | 15.01 | 49.98 | 64.01 | 61.04 | 120 | 97.97 |
| Tax % | 82.9% | 66.9% | 11.9% | 50.9% | 50.9% | 23.9% | 5.0% | 5.0% | 32.0% | 27.0% | 9.9% | −3.0% |
| Exceptional items | 0.00 | 0.00 | 4.01 | 0.00 | 0.00 | 0.00 | −20.01 | 0.00 | 0.00 | −8.99 | 22.02 | 0.00 |
| Net Profit | 1.99 | 4.99 | 23.96 | 13.98 | 17.98 | 31.97 | 14.99 | 46.96 | 43.95 | 44.97 | 108 | 101 |
| EPS (Rs) | 0.08 | 0.25 | 1.40 | 0.71 | 0.91 | 1.61 | 0.73 | 2.39 | 2.24 | 2.27 | 5.50 | 5.15 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 716 | 776 | 786 | 731 | 905 | 896 | 1,136 | 1,042 | 1,141 | 1,277 | 1,533 | 1,676 |
| Expenses | 568 | 616 | 636 | 587 | 691 | 721 | 943 | 951 | 910 | 968 | 1,107 | 1,209 |
| Operating Profit | 152 | 164 | 154 | 147 | 218 | 180 | 201 | 98.65 | 238 | 315 | 433 | 476 |
| OPM % | 21.0% | 21.0% | 20.0% | 20.0% | 24.0% | 20.0% | 18.0% | 9.0% | 21.0% | 25.0% | 28.0% | 28.4% |
| Other Income | 4.99 | 14.98 | 21.96 | 32.93 | 16.97 | 89.82 | 20.95 | 16.98 | 14.97 | −4.99 | 38.95 | 42.94 |
| Interest | 6.99 | 2.99 | 2.99 | 3.99 | 4.99 | 21.99 | 40.99 | 58.97 | 91.97 | 75.92 | 58.93 | 52.94 |
| Depreciation | 29.08 | 31.07 | 37.09 | 42.10 | 44.10 | 54.13 | 80.27 | 96.32 | 108 | 113 | 120 | 126 |
| Profit before tax | 122 | 146 | 137 | 136 | 188 | 195 | 102 | −37.99 | 53.97 | 122 | 295 | 343 |
| Tax % | 18.9% | 28.9% | 25.0% | 18.9% | 17.9% | 24.9% | 41.0% | −19.1% | 40.9% | 35.9% | 17.9% | — |
| Exceptional items | 0.00 | 4.01 | 8.99 | 16.01 | 0.00 | 44.99 | 4.01 | 0.00 | 1.01 | −10.01 | 10.01 | 13.03 |
| Net Profit | 98.93 | 104 | 103 | 110 | 155 | 146 | 60.90 | −30.94 | 31.94 | 77.93 | 243 | 298 |
| EPS (Rs) | 6.71 | 6.70 | 6.43 | 6.86 | 9.55 | 9.04 | 3.48 | −1.86 | 1.83 | 3.99 | 12.41 | 15.16 |
| Dividend payout % | 4.0% | 4.0% | 5.0% | 7.0% | 6.0% | 6.0% | 16.0% | 0.0% | 0.0% | 12.0% | 5.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.03 | 8.03 | 8.02 | 8.03 | 8.02 | 8.02 | 8.01 | 9.02 | 9.02 | 9.03 | 10.02 | 20.06 |
| Reserves | 540 | 641 | 981 | 1,080 | 1,191 | 1,322 | 1,473 | 1,818 | 1,778 | 1,803 | 2,365 | 2,577 |
| Borrowings | 189 | 222 | 241 | 191 | 194 | 390 | 847 | 684 | 800 | 939 | 589 | 661 |
| Other Liabilities | 168 | 193 | 243 | 222 | 217 | 269 | 307 | 368 | 321 | 345 | 349 | 453 |
| Total Liabilities | 906 | 1,064 | 1,473 | 1,501 | 1,611 | 1,990 | 2,634 | 2,879 | 2,908 | 3,096 | 3,313 | 3,710 |
| Fixed Assets | 317 | 582 | 493 | 536 | 560 | 652 | 1,114 | 1,345 | 1,372 | 1,389 | 1,422 | 2,051 |
| CWIP | 221 | 94.81 | 141 | 210 | 428 | 665 | 539 | 505 | 653 | 717 | 820 | 430 |
| Investments | 66.04 | 53.01 | 253 | 140 | 1.99 | 9.99 | 20.99 | 33.98 | 43.03 | 40.01 | 35.02 | 58.04 |
| Other Assets | 301 | 334 | 588 | 616 | 621 | 662 | 959 | 994 | 839 | 951 | 1,037 | 1,171 |
| Inventories | 130 | 163 | 189 | 188 | 187 | 225 | 316 | 354 | 319 | 344 | 347 | 366 |
| Trade receivables | 80.71 | 84.78 | 170 | 219 | 203 | 246 | 217 | 384 | 323 | 390 | 439 | 518 |
| Cash & equivalents | 17.92 | 15.94 | 99.65 | 73.75 | 94.59 | 44.84 | 123 | 33.88 | 21.91 | 31.88 | 28.88 | 44.81 |
| Total Assets | 906 | 1,064 | 1,473 | 1,501 | 1,611 | 1,990 | 2,634 | 2,879 | 2,908 | 3,096 | 3,313 | 3,710 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 68.80 | 129 | 36.89 | 44.87 | 147 | 124 | 46.85 | 105 | 180 | 137 | 132 | 341 |
| Cash from investing activity | −196 | −106 | −257 | −10.01 | −196 | −290 | −404 | −286 | −232 | −171 | −198 | −326 |
| Cash from financing activity | 136 | −20.03 | 313 | −61.15 | 10.02 | 176 | 437 | 83.16 | 46.06 | 47.11 | 63.11 | 14.02 |
| Net cash flow | 8.97 | 2.99 | 92.73 | −25.90 | −38.88 | 9.98 | 78.76 | −97.67 | −6.97 | 12.96 | −2.99 | 29.89 |
| Capex | 145 | 117 | 117 | 138 | 80.92 | 349 | 354 | 332 | 227 | 185 | 244 | 371 |
| Free cash flow | −73.89 | 11.97 | −78.80 | −91.85 | −151 | −219 | −302 | −226 | −45.90 | −47.94 | −111 | −14.97 |
| CFO / OP % | 73.0% | 103.0% | 43.0% | 55.0% | 123.0% | 76.0% | 52.0% | 69.0% | 215.0% | 74.0% | 57.0% | 93.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 48 | 43 | 80 | 102 | 101 | 99 | 88 | 124 | 113 | 125 | 126 | 123 |
| Inventory days | 147 | 161 | 187 | 194 | 266 | 298 | 427 | 338 | 280 | 309 | 309 | 291 |
| Days payable | 84 | 100 | 109 | 105 | 114 | 121 | 90 | 138 | 124 | 155 | 84 | 112 |
| Cash conversion cycle | 111 | 104 | 157 | 189 | 253 | 275 | 425 | 323 | 268 | 278 | 350 | 301 |
| Working capital days | 34 | 28 | 80 | 99 | 99 | 69 | 73 | 78 | −12 | 49 | 82 | 52 |
| ROCE % | 18.0% | 15.9% | 13.9% | 9.9% | 9.0% | 11.9% | 8.0% | 6.0% | 1.0% | 5.0% | 7.9% | 10.9% |
For the Jun 2026 quarter, Shilpa Medicare reported sales of ₹464 Cr, up 45.1% year on year and net profit of ₹101 Cr, up 114.9% year on year. The operating margin was 29.0%.
Shilpa Medicare's sales for the year to Mar 2026 were ₹1,533 Cr; over the last twelve months they were ₹1,676 Cr.
Net profit for the year to Mar 2026 was ₹243 Cr, and ₹298 Cr over the last twelve months. Earnings per share over the same trailing period were ₹15.16.
Shilpa Medicare reported borrowings of ₹661 Cr at Mar 2026, against cash and equivalents of ₹44.81 Cr.
Cash from operations was ₹341 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹14.97 Cr.